Last updated on July 2019

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease


Brief description of study

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.

Clinical Study Identifier: NCT03939767

Find a site near you

Start Over

Many Locations

Multiple Locations, Argentina
  Connect »

Many Locations

Multiple Locations, Australia
  Connect »

Many Locations

Multiple Locations, Belgium
  Connect »

Many Locations

Multiple Locations, Canada
  Connect »

Many Locations

Multiple Locations, China
  Connect »

Many Locations

Multiple Locations, Denmark
  Connect »

Many Locations

Multiple Locations, France
  Connect »

Many Locations

Multiple Locations, Greece
  Connect »

Many Locations

Multiple Locations, Ireland
  Connect »

Many Locations

Multiple Locations, Korea, Republic of
  Connect »

Many Locations

Multiple Locations, Norway
  Connect »

Many Locations

Multiple Locations, Spain
  Connect »

Many Locations

Multiple Locations, Sweden
  Connect »

Many Locations

Multiple Locations, Thailand
  Connect »

Many Locations

Multiple Locations, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.